TABLE 2

Retinopathy outcomes during the first 4 and 10 years of EDIC follow-up among adolescents free of that outcome at DCCT closeout who had retinopathy evaluated at EDIC year 10

Retinopathy outcome*DCCT closeoutEDIC year 4EDIC year 10
INTCONOdds reduction (95% CI)PINTCONOdds reduction (95% CI)PINTCONOdds reduction (95% CI)P
≥Three-step progression from DCCT baseline (%)26.048.262 (23–81)0.004419.245.571 (23–90)0.014450.953.410 (−104 to 60)0.8395
    n738347335343
SNPDR+ (%)5.57.223 (−177 to 80)0.65721.616.191 (31–98)0.008511.619.546 (−37 to 79)0.2560
    n738362626977
PDR+ (%)5.57.223 (−177 to 80)0.65621.69.785 (−32 to 98)0.114311.618.241 (−52 to 77)0.3550
    n738362626977
CSME (%)5.52.7−108 (−1,076 to 63)0.89863.21.7−96 (−2,122 to 83)1.00011.66.9−75 (−488 to 45)0.3932
    n737462606972
Photocoagulation therapy (focal or scatter) (%)5.54.8−15 (−376 to 72)0.85200.05.1NA0.12337.317.764 (−11 to 88)0.0834
    n738369796979
  • *Patients with scatter photocoagulation after entry into the DCCT were counted as worse for retinopathy; those with focal photocoagulation were counted as worse for macular edema.

  • †INT is the former DCCT intensive group and CON is the former DCCT conventional group.

  • ‡The odds reduction is for intensive therapy compared with conventional therapy. CSME, clinically significant macular edema; PDR+, proliferative diabetic retinopathy or worse; SNPDR+, severe nonproliferative retinopathy or worse. Data in boldface are statistically significant.